This retrospective, nationwide study suggests that combination therapy with SGLT2 inhibitors and RAS inhibitors may offer greater renal and survival benefits for diabetic patients with hypertension compared to either SGLT2 inhibitors or RAS inhibitors alone, or to those not receiving either therapy. Here, SLC5A2 is linked to hypertensive disorder.